Sign up Australia
Proactive Investors - Run By Investors For Investors

AusCann Group secures $33.4 million to fund ambitious medicinal cannabis future

An $8 million share purchase plan (SPP) will follow the placement.
three hands dropping coins into three jars
The aim is to provide Australian and global markets with medicinal cannabis products

AusCann Group Holdings Ltd (ASX:AC8) has raised $33.4 million via a share placement to institutional and sophisticated investors from North America and Australia.

Proceeds will fund cannabinoid pharmaceutical R&D and clinical studies, expansion of its operations in Chile and Australia and medical outreach programs in new international markets.

Efficacious, clinically validated and cost-effective medicinal cannabis products

AusCann’s managing director Elaine Darby said: “We are very pleased to offer both new and existing shareholders the opportunity to participate in the evolution of AusCann.

"The capital we secure from this raising will enable us to accelerate our corporate objectives and provide Australian and global markets with efficacious, clinically validated and cost-effective medicinal cannabis products.”

READ: AusCann Group Holdings to accelerate medical cannabis strategy through master grower appointment

The placement will see 30.4 million shares issued at $1.10 and placement participants will also receive 1 option for every 2 shares subscribed for exercisable at A$1.465 expiring in 30 months.

$8 million share purchase plan to follow

AusCann intends to offer a share purchase plan (SPP) raising up to $8 million to eligible existing shareholders, providing an opportunity for shareholders to purchase shares at the placement price.

This will also provide an extra avenue of funding for AusCann.

Funds to go towards a number of initiatives

It is intended that funds raised under the placement will be used as follows:

• Clinical studies for product registration in Australia;
• Expansion of an Australian manufacturing plant for final dose form manufacturing;
• Establishment of a manufacturing facility in Chile;
• Establishment medical outreach programs in new international markets;
• Research and development of cannabinoid pharmaceuticals; and
• Costs of the offer and general working capital requirements.

Join our Crypto, Blockchain and Cannabis Telegram group here
View full AC8 profile View Profile

AusCann Group Holdings Ltd Timeline

Related Articles

Vial of pills
June 25 2018
Cosmos is a modern company, but the trade routes it relies on are ancient
Cancer cells
June 27 2018
The Nottingham-based privately-owned company has made an impressive fist of developing the OMIS (Opto-magnetic Imaging Spectroscopy) cancer detection system
woman at a microscope
August 02 2018
Currently undergoing phase III clinical trials, AP101 is being developed to treat Epidermolysis Bullosa, a condition which occurs prominently in children and makes skin fragile to even the faintest touch

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use